Your browser doesn't support javascript.
loading
Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy.
Darwich, Adam S; Polasek, Thomas M; Aronson, Jeffrey K; Ogungbenro, Kayode; Wright, Daniel F B; Achour, Brahim; Reny, Jean-Luc; Daali, Youssef; Eiermann, Birgit; Cook, Jack; Lesko, Lawrence; McLachlan, Andrew J; Rostami-Hodjegan, Amin.
Afiliación
  • Darwich AS; Logistics and Informatics in Health Care, School of Engineering Sciences in Chemistry, Biotechnology and Health (CBH), KTH Royal Institute of Technology, SE-141 57 Huddinge, Sweden.
  • Polasek TM; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia 5000, Australia.
  • Aronson JK; Centre for Medicine Use and Safety, Monash University, Melbourne, Victoria 3052, Australia.
  • Ogungbenro K; Certara, Princeton, New Jersey 08540, USA.
  • Wright DFB; Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, United Kingdom.
  • Achour B; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester M13 9PT, United Kingdom; email: amin.rostami@manchester.ac.uk.
  • Reny JL; School of Pharmacy, University of Otago, Dunedin 9054, New Zealand.
  • Daali Y; Centre for Applied Pharmacokinetic Research, The University of Manchester, Manchester M13 9PT, United Kingdom; email: amin.rostami@manchester.ac.uk.
  • Eiermann B; Geneva Platelet Group, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
  • Cook J; Division of General Internal Medicine, Geneva University Hospitals, CH-1211 Geneva, Switzerland.
  • Lesko L; Geneva Platelet Group, Faculty of Medicine, University of Geneva, CH-1211 Geneva, Switzerland.
  • McLachlan AJ; Inera AB, Swedish Association of Local Authorities and Regions, SE-118 93 Stockholm, Sweden.
  • Rostami-Hodjegan A; Drug Safety Research & Development, Pfizer Inc., Groton, Connecticut 06340, USA.
Annu Rev Pharmacol Toxicol ; 61: 225-245, 2021 01 06.
Article en En | MEDLINE | ID: mdl-33035445
Model-informed precision dosing (MIPD) has become synonymous with modern approaches for individualizing drug therapy, in which the characteristics of each patient are considered as opposed to applying a one-size-fits-all alternative. This review provides a brief account of the current knowledge, practices, and opinions on MIPD while defining an achievable vision for MIPD in clinical care based on available evidence. We begin with a historical perspective on variability in dose requirements and then discuss technical aspects of MIPD, including the need for clinical decision support tools, practical validation, and implementation of MIPD in health care. We also discuss novel ways to characterize patient variability beyond the common perceptions of genetic control. Finally, we address current debates on MIPD from the perspectives of the new drug development, health economics, and drug regulations.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Desarrollo de Medicamentos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Año: 2021 Tipo del documento: Article País de afiliación: Suecia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Desarrollo de Medicamentos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Annu Rev Pharmacol Toxicol Año: 2021 Tipo del documento: Article País de afiliación: Suecia